Intellia Therapeutics (NTLA) EBIT (2015 - 2026)
Intellia Therapeutics (NTLA) reported EBIT of -$100.5 million for Q1 2026, up 16.78% year-over-year from -$86.1 million in Q1 2025, and down 1.85% on a QoQ basis from -$98.7 million in Q4 2025.
Intellia Therapeutics (NTLA) has 12 years of EBIT data on file, last reported at -$100.5 million in Q1 2026.
- Quarterly EBIT rose 16.78% year-over-year to -$100.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$420.7 million (up 22.24% YoY) and the FY2025 annual result came in at -$441.0 million, up 17.46% from the prior year.
- EBIT retreated to -$100.5 million in Q1 2026 per NTLA's latest filing, from -$98.7 million in the prior quarter.
- Across five years, EBIT topped out at -$98.3 million in Q2 2022 and bottomed at -$144.8 million in Q3 2024.
- The 5-year median for EBIT is -$114.0 million (2024), against an average of -$120.5 million.
- The widest annual swing landed in 2022, when EBIT slumped 210.71%; it then rose 27.66% in 2025.
- Tracing NTLA's EBIT over 5 years: stood at -$110.1 million in 2022, then slipped by 27.07% to -$139.9 million in 2023, then advanced by 2.46% to -$136.4 million in 2024, then advanced by 27.66% to -$98.7 million in 2025, then declined by 1.85% to -$100.5 million in 2026.
- Per Business Quant, the three latest NTLA EBIT figures stand at -$100.5 million (Q1 2026), -$98.7 million (Q4 2025), and -$111.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Intellia Therapeutics | 1.63 Bn | 1.63 Bn | - | -100.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -100.53 Mn |
| Dec 31, 2025 | -98.71 Mn |
| Sep 30, 2025 | -111.48 Mn |
| Jun 30, 2025 | -110.00 Mn |
| Mar 31, 2025 | -120.81 Mn |
| Dec 31, 2024 | -136.45 Mn |
| Sep 30, 2024 | -144.77 Mn |
| Jun 30, 2024 | -139.04 Mn |
| Mar 31, 2024 | -114.00 Mn |
| Dec 31, 2023 | -139.89 Mn |
| Sep 30, 2023 | -131.11 Mn |
| Jun 30, 2023 | -132.33 Mn |
| Mar 31, 2023 | -111.96 Mn |
| Dec 31, 2022 | -110.09 Mn |
| Sep 30, 2022 | -105.53 Mn |
| Jun 30, 2022 | -98.30 Mn |
| Mar 31, 2022 | -144.25 Mn |
| Dec 31, 2021 | -80.42 Mn |
| Sep 30, 2021 | -71.99 Mn |
| Jun 30, 2021 | -69.02 Mn |
| Mar 31, 2021 | -46.43 Mn |
| Dec 31, 2020 | -42.40 Mn |
| Sep 30, 2020 | -28.10 Mn |
| Jun 30, 2020 | -33.03 Mn |
| Mar 31, 2020 | -33.05 Mn |
| Dec 31, 2019 | -29.77 Mn |
| Sep 30, 2019 | -25.33 Mn |
| Jun 30, 2019 | -27.46 Mn |
| Mar 31, 2019 | -23.81 Mn |
| Dec 31, 2018 | -20.75 Mn |
| Sep 30, 2018 | -24.10 Mn |
| Jun 30, 2018 | -23.60 Mn |
| Mar 31, 2018 | -22.43 Mn |
| Dec 31, 2017 | -24.72 Mn |
| Sep 30, 2017 | -15.88 Mn |
| Jun 30, 2017 | -16.02 Mn |
| Mar 31, 2017 | -12.95 Mn |
| Dec 31, 2016 | -10.82 Mn |
| Sep 30, 2016 | -7.70 Mn |
| Jun 30, 2016 | -6.95 Mn |
| Mar 31, 2016 | -6.69 Mn |
| Dec 31, 2015 | -5.49 Mn |
| Sep 30, 2015 | -3.30 Mn |
| Jun 30, 2015 | -3.42 Mn |
| Mar 31, 2015 | -1.20 Mn |